All In Biotech

Drug Trial Radar · NCT03900442

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Sep 1, 2019

Primary completion

Jul 31, 2025

Study completion Aug 8, 2025

Sponsor

Lead sponsor
Prescient Therapeutics, Ltd.Industry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.

Conditions

  • Advanced Cancer
  • PTCL

Interventions

  • PTX-100Drug

    Doses of 500 to 2000 mg/m2 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (RAP-1)Time frame: One Cycle (cycle = 14 days)
  2. Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (PD endpoints)Time frame: One Cycle (cycle = 14 days)
  3. Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (cmax)Time frame: One Cycle (cycle = 14 days)
  4. Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (Tmax)Time frame: One Cycle (cycle = 14 days)
  5. Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (half life)Time frame: One Cycle (cycle = 14 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Epworth Healthcare

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.